CMA to investigate Roche's acquisition of Spark Therapeutics
The Competition and Markets Authority said on Tuesday that is launching an investigation into Roche's planned $4.8bn acquisition of Philadelphia-based gene therapy developer Spark Therapeutics.
The competition watchdog said it will look into whether the deal will result in a "substantial lessening" of competition.
The deadline for the phase 1 decision is 16 December.
Swiss drug maker Roche announced in February that it had agreed to buy Spark for $114.50 a share.